PLOS Medicine 'Under Review': What Each Status Means and When to Expect a Decision

Before the paper reaches Academic Editor assignment, a PLOS Medicine in-house handling editor evaluates whether the work warrants the Academic Editor + peer-review process. The assessment focuses on scope, whether the methods are presented in sufficient detail for review purposes, the overall quality of the language, and whether the research was conducted with appropriate ethical approval and meets high ethical standards. About 80 percent of submissions are declined at this initial screening within 1 to 2 weeks.

A decline at screening most often means the in-house handling editor concluded that the work is outside PLOS Medicine's editorial scope or that the methods documentation is insufficient.

The PLOS Medicine editorial office checks whether the package is reviewable: manuscript file, figures, supporting information, trial registration where applicable, ethics approvals, competing-interest statements, data-availability language, and reporting checklists such as CONSORT, STROBE, PRISMA, or ARRIVE. The practical risk is not only missing files; it is a methods section or data statement that cannot support the clinical or policy claim in the abstract.

The PLOS Medicine in-house handling editor reads the paper and evaluates scope, methods detail, language quality, and ethical approval. The initial submission process allows authors to quickly submit and obtain rapid feedback from the editors.

Papers that pass initial screening are assigned to a PLOS Medicine Academic Editor (a working academic on the Editorial Board). The Academic Editor identifies and invites external reviewers with topic-matched expertise. Academic Editors assess the manuscript against publication criteria, paying particular attention to whether the conclusions are supported by the data provided.

PLOS Medicine Academic Editors typically invite 2 to 3 external reviewers. The recruitment window can take 7 to 14 days because reviewers with topic-matched general-medicine clinical-research expertise are scarce.

Once reviewers agree to review, the typical PLOS Medicine peer-review cycle lasts 4 to 10 weeks per reviewer. Reviewers are asked to evaluate general-medicine relevance, methodological rigor, statistical methodology, and reproducibility. PLOS Medicine operates a transparent peer-review model; reviewer reports can be published alongside accepted papers.

After reports return, the Academic Editor synthesizes them and presents the case to the in-house handling editor for final decision. The editors make the final decision on whether to publish each submission based on the reviewers' comments, the PLOS Medicine criteria for publication, and their own assessment of the manuscript.

• Decline within 1 to 5 days: Administrative issue or immediate scope mismatch.

• Decline within 1 to 2 weeks: In-house editor initial screening decline per the 80 percent figure.

• Still Under Review after 3 weeks: Strong signal. Paper passed the in-house editor screening.

• Still Under Review after 14 weeks: Reviewer-recruitment or reviewer-report delay. A polite inquiry via the Editorial Manager portal is appropriate.

• Status changes to "Decision Pending": Reports are in; expect a decision within 1 to 2 weeks.

This is the most common anxiety we hear from PLOS Medicine authors during the active editorial window. The honest answer: no, 8 weeks at Under Review puts you in the normal middle of PLOS Medicine's 8 to 14 week post-screen first-decision distribution. Reports may already be in editorial synthesis with the Academic Editor preparing the recommendation for the in-house handling editor's final decision.

Most reviewer-driven delays come from reviewer-recruitment timing rather than slow reviews because PLOS Medicine recruits topic-matched general-medicine clinical-research reviewers under a transparent peer-review model. If the portal still says Under Review at the 12-week mark, the most likely explanation is that one of the assigned reviewers asked for an extension and the Academic Editor granted it. This is normal practice at PLOS Medicine.

The better use of the 8-to-12-week window is to audit the revision package reviewers are likely to request: abstract clinical or policy claim, first table and figure logic, statistical-methods detail, data availability, ethics documentation, and the response-letter skeleton. A status note at 8 weeks rarely changes reviewer behavior, but a prepared response file can shorten a later revision by several days.

If your PLOS Medicine paper is rejected after review, the natural cascade depends on what the reviewers and editor cited:

PLOS ONE is the natural PLOS cascade for clinical-research papers where the general-medicine relevance bar of PLOS Medicine is not met but the rigor is high. PLOS supports manuscript-transfer with reviewer reports preserved.

PLOS Global Public Health is the PLOS cascade for global-health-focused clinical-research papers.

PLOS Digital Health is the PLOS cascade for digital-health and AI-clinical-research papers.

BMJ Open is the BMJ open-access general-medicine cascade. BMJ Open uses ScholarOne at ScholarOne submission portal; editorial contact editorial.bmjopen@bmj.com.

The Lancet Public Health is the Lancet specialty open-access cascade for public-health clinical-research. The Lancet uses Editorial Manager at Editorial Manager submission portal; editorial contact editorial@lancet.com.

NEJM Evidence is the NEJM open-access cascade for clinical-research papers. NEJM uses ScholarOne at ScholarOne submission portal; editorial contact nejm@nejm.org.

PLOS Medicine asks reviewers to evaluate four things specifically. The table below maps each to actionable preparation.

In our pre-submission work with PLOS Medicine-targeted manuscripts, three named patterns generate the most consistent reviewer concerns and the most common reasons papers miss the editorial bar or fail the initial screening.

Specialty-only framing flagged at in-house editor initial screening. When the introduction frames the work too narrowly without general-medicine readership relevance, in-house handling editor initial screening decline within 1 to 2 weeks is common. The strongest manuscripts frame the introduction around an implication for general-medicine practice that would matter to the broad PLOS Medicine readership.

Check whether your PLOS Medicine framing reaches a general-medicine audience →

Methods documentation gaps surface at initial screening. When methods documentation is thin (especially for specialized techniques, custom analysis pipelines, or complex statistical models), the in-house handling editor consistently flags concerns at initial screening before Academic Editor assignment. The strongest manuscripts include methods sufficient for replication before submission.

Check whether your methods section is reviewable →

Data-conclusion alignment flagged by Academic Editor. When conclusions exceed what the data clearly support (especially causal claims from observational data or generalization claims from limited samples), Academic Editors consistently flag concerns paying particular attention to whether the conclusions are supported by the data provided. The strongest manuscripts make conservative conclusions that the data clearly support.

Check whether your conclusions stay inside the data →

We have reviewed 50+ manuscripts targeting PLOS Medicine, BMJ, The Lancet, BMC Medicine, PLOS ONE, and adjacent clinical-research venues. Full Manusights reviews include a 60-day money-back guarantee, and we do not train models on your manuscript.

In our pre-submission review work across general-medicine and clinical-research targets, we see five recurring preventable risks before peer review: specialty-only framing, unsupported policy or practice claims, under-specified statistical methods, incomplete data-availability routes, and reporting checklists that do not map cleanly to the manuscript. Source limitation: Official guidance explains the process, publication criteria, and portal route, but it cannot diagnose whether your specific abstract, tables, methods, and data package will satisfy the professional editor and Academic Editor.

This page was created from PLOS Medicine's public Editorial and Peer Review Process documentation at Journals editorial team page, PLOS Medicine submission guidelines documentation (initial screening process, Academic Editor administration of peer review, criteria-based publication decisions, transparent peer-review option), SciRev community-reported transit data on PLOS Medicine, and Manusights pre-submission review experience with PLOS Medicine-targeted manuscripts.

For the PLOS general-medicine landscape beyond PLOS Medicine, see PLOS ONE (technically-sound open-access cascade), PLOS Global Public Health (global-health specialty), PLOS Digital Health (digital-health and AI-clinical-research specialty), and external general-medicine open-access alternatives (BMJ Open, The Lancet Public Health, NEJM Evidence).

The choice across these titles depends on whether the central contribution is top-tier PLOS general-medicine clinical-research (PLOS Medicine), technically-sound open-access (PLOS ONE), global-health-focused (PLOS Global Public Health), digital-health-focused (PLOS Digital Health), or external general-medicine open-access (BMJ Open, Lancet Public Health, NEJM Evidence).

Reviewers at PLOS Medicine typically draw from one general-medicine clinical specialist and one methodologist or biostatistician. Editors screen and triage manuscripts before any Academic Editor or external reviewer sees them, and preparing a response template that addresses both general-medicine relevance and methods detail accelerates revision rounds substantially.

For a pre-upload check of your manuscript against the PLOS Medicine general-medicine-relevance-plus-methods-detail bar before submission, our PLOS Medicine pre-submission diagnostic flags the framing and methods-documentation weaknesses most likely to surface in reviewer reports.